Literature DB >> 16989012

Natural killer cells play a key role in the antitumor immunity generated by chaperone-rich cell lysate vaccination.

Yi Zeng1, Xinchun Chen, Nicolas Larmonier, Claire Larmonier, Gang Li, Marjan Sepassi, Marilyn Marron, Samita Andreansky, Emmanuel Katsanis.   

Abstract

Tumor derived chaperone-rich cell lysate (CRCL) when isolated from tumor tissues is a potent vaccine that contains at least 4 of the highly immunogenic heat shock proteins (HSP) such as HSP70, HSP90, glucose related protein 94 and calreticulin. We have previously documented that CRCL provides both a source of tumor antigens and danger signals triggering dendritic cell (DC) activation. Immunization with tumor derived CRCL elicits tumor-specific T cell responses leading to tumor regression. In the current study, we further dissect the mechanisms by which CRCL simulates the immune system, and demonstrate that natural killer (NK) cells are required for effective antitumor effects to take place. Our results illustrate that CRCL directly stimulates proinflammatory cytokine and chemokine production by NK cells, which may lead to activation and recruitment of macrophages at the tumor site. Thus, this report provides further insight into the function of CRCL as an immunostimulant against cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16989012     DOI: 10.1002/ijc.22150

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  Exosomes from Dendritic Cells Loaded with Chaperone-Rich Cell Lysates Elicit a Potent T Cell Immune Response Against Intracranial Glioma in Mice.

Authors:  Ning Bu; Haiqin Wu; Guilian Zhang; Shuqin Zhan; Ru Zhang; Hong Sun; Yun Du; Li Yao; Huqing Wang
Journal:  J Mol Neurosci       Date:  2015-02-14       Impact factor: 3.444

Review 2.  Targeting Hsp70: A possible therapy for cancer.

Authors:  Sanjay Kumar; James Stokes; Udai P Singh; Karyn Scissum Gunn; Arbind Acharya; Upender Manne; Manoj Mishra
Journal:  Cancer Lett       Date:  2016-02-17       Impact factor: 8.679

Review 3.  Personalized dendritic cell-based tumor immunotherapy.

Authors:  Nona Janikashvili; Nicolas Larmonier; Emmanuel Katsanis
Journal:  Immunotherapy       Date:  2010-01       Impact factor: 4.196

4.  Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors.

Authors:  Nicolas Larmonier; Nona Janikashvili; Collin James LaCasse; Claire Billerey Larmonier; Jessica Cantrell; Elaine Situ; Tamara Lundeen; Bernard Bonnotte; Emmanuel Katsanis
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

Review 5.  The therapeutic implications of clinically applied modifiers of heat shock protein 70 (Hsp70) expression by tumor cells.

Authors:  Mathias Gehrmann; Jürgen Radons; Michael Molls; Gabriele Multhoff
Journal:  Cell Stress Chaperones       Date:  2008-02-05       Impact factor: 3.667

Review 6.  Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference.

Authors:  Nathalie Chaput; Stéphane De Botton; Michel Obeid; Lionel Apetoh; François Ghiringhelli; Theocharis Panaretakis; Caroline Flament; Laurence Zitvogel; Guido Kroemer
Journal:  J Mol Med (Berl)       Date:  2007-05-22       Impact factor: 4.599

7.  Expression of heat shock protein 70 in nasopharyngeal carcinomas: different expression patterns correlate with distinct clinical prognosis.

Authors:  Man-Bo Cai; Xiao-Pai Wang; Jia-Xing Zhang; Hui-Qiong Han; Chao-Chun Liu; Jin-Xin Bei; Ruo-Jun Peng; Yi Liang; Qi-Sheng Feng; Hai-Yun Wang; Li-Zhen Chen; Sha Fu; Tiebang Kang; Jian-Yong Shao; Yi-Xin Zeng
Journal:  J Transl Med       Date:  2012-05-16       Impact factor: 5.531

Review 8.  Endoplasmic reticulum chaperones and their roles in the immunogenicity of cancer vaccines.

Authors:  Michael W Graner; Kevin O Lillehei; Emmanuel Katsanis
Journal:  Front Oncol       Date:  2015-01-06       Impact factor: 6.244

9.  Recombinant heat shock protein 70 in combination with radiotherapy as a source of tumor antigens to improve dendritic cell immunotherapy.

Authors:  Yu-Shan Wang; Shih-Jen Liu; Su-Chen Huang; Chao-Chun Chang; Yi-Chun Huang; Weng-Lam Fong; Mau-Shin Chi; Kwan-Hwa Chi
Journal:  Front Oncol       Date:  2012-10-29       Impact factor: 6.244

10.  Pilot study of intratumoral injection of recombinant heat shock protein 70 in the treatment of malignant brain tumors in children.

Authors:  Maxim A Shevtsov; Alexander V Kim; Konstantin A Samochernych; Irina V Romanova; Boris A Margulis; Irina V Guzhova; Igor V Yakovenko; Alexander M Ischenko; William A Khachatryan
Journal:  Onco Targets Ther       Date:  2014-06-18       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.